Novel therapeutics for portal hypertension and fibrosis in chronic liver disease.

BORIS DOI
Publisher DOI
PubMed ID
32659305
Description
Portal hypertension (PH) is the most common non-neoplastic complication of chronic liver disease, determining clinical complications that lead to death or liver transplantation. PH results from increased resistance to portal blood flow through the cirrhotic liver, which is due to hepatic fibrosis and microcirculatory dysfunction. The present review focuses on the pathophysiology of fibrosis and PH, describes currently used treatments, and critically discusses potential therapeutic options.
Date of Publication
2020-11
Publication Type
Article
Subject(s)
Keyword(s)
Cirrhosis Hepatic hemodynamic Hepatic stellate cells Liver microcirculation Portal pressure
Language(s)
en
Contributor(s)
Zhu, Chang-Peng
Xie, Wei-Fen
Additional Credits
Series
Pharmacology & therapeutics
Publisher
Elsevier
ISSN
0163-7258
Access(Rights)
restricted
Show full item